Competing risks and the clinical community: irrelevance or ignorance?

Abstract

Life expectancy has dramatically increased in industrialized nations over the last 200 hundred years. The aging of populations carries over to clinical research and leads to an increasing representation of elderly and multimorbid individuals in study populations. Clinical research in these populations is complicated by the fact that individuals are likely to experience several potential disease endpoints that prevent some disease‐specific endpoint of interest from occurrence. Large developments in competing risks methodology have been achieved over the last decades, but we assume that recognition of competing risks in the clinical community is still marginal. It is the aim of this article to address translational aspects of competing risks to the clinical community. We describe clinical populations where competing risks issues may arise. We then discuss the importance of agreement between the competing risks methodology and the study aim, in particular the distinction between etiologic and prognostic research questions. In a review of 50 clinical studies performed in individuals susceptible to competing risks published in high‐impact clinical journals, we found competing risks issues in 70% of all articles. Better recognition of issues related to competing risks and of statistical methods that deal with competing risks in accordance with the aim of the study is needed. Copyright © 2011 John Wiley & Sons, Ltd.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 35

1. 1.

   Varadhan R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C. Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Medical Care. 2010;48(6 Suppl):S96-S105.

   Not in our library10.1097/mlr.0b013e3181d99107

2. 2.

   Statistics Norway.

   Not in our library

3. 3.

   Spillman BC, Lubitz J. The effect of longevity on spending for acute and long-term care. The New England Journal of Medicine. 2000;342(19):1409-1415.

   Not in our library10.1056/nejm200005113421906

4. 4.

   Hanchate A, Kronman AC, Young-Xu Y, Ash AS, Emanuel E. Racial and ethnic differences in end-of-life costs: why do minorities cost more than whites? Archives of Internal Medicine. 2009;169(5):493-501.

   Not in our library10.1001/archinternmed.2008.616

5. 5.

   Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church T, et al. Mortality results from a randomized prostate-cancer screening trial. The New England Journal of Medicine. 2009;360(13):1310-1319.

   Not in our library10.1056/nejmoa0810696

6. 6.

   Wolkewitz M, Vonberg RP, Grundmann H, Beyersmann J, Gastmeier P, Barwolff S. et al. Risk factors for the development of nosocomial pneumonia and mortality on intensive care units: application of competing risks models. Crital Care. 2008;12(2):R44.

   Not in our library10.1186/cc6852

7. 7.

   Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Statistics in Medicine. 2007;26(11):2389-2430.

   Not in our library10.1002/sim.2712

8. 8.

   Andersen PK, Abildstrom SZ, Rosthoj S. Competing risks as a multi-state model. Statistical Methods in Medical Research. 2002;11(2):203-215.

   Not in our library10.1191/0962280202sm281ra

9. 9.

   Beyersmann J, Latouche A, Buchholz A, Schumacher M. Simulating competing risks data in survival analysis. Statistics in Medicine. 2009;28(6):956-971.

   Not in our library10.1002/sim.3516

10. 10.

    Beyersmann J, Schumacher M. Misspecified regression model for the subdistribution hazard of a competing risk. Statistics in Medicine. 2007;26(7):1649-1651.

    Not in our library10.1002/sim.2727

11. 11.

    Beyersmann J, Dettenkofer M, Bertz H, Schumacher M. A competing risks analysis of bloodstream infection after stem-cell transplantation using subdistribution hazards and cause-specific hazards. Statistics in Medicine. 2007;26(30):5360-5369.

    Not in our library10.1002/sim.3006

12. 12.

    Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association. 1999;94(446):496-509.

    Not in our library

13. 13.

    Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. American Journal of Epidemiology. 2009;170(2):244-256.

    Not in our library10.1093/aje/kwp107

14. 14.

    Tsiatis A. A nonidentifiability aspect of the problem of competing risks. Proceedings of the National Academy of Sciences of the United States of America. 1975;72:20-22.

    Not in our library10.1073/pnas.72.1.20

15. 15.

    Greenland S, Murray CJL, Salomon JA, Mathers CD, Lopez AD. Causality theory for policy uses of epidemiological measures. Summary measures of Population Health. 2002;291.

    Not in our library

16. 16.

    Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine. 1999;18(6):695-706.

    Not in our library10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o

17. 17.

    Geskus RB. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring. Biometrics. 2011;67(1):39-49.

    Not in our library10.1111/j.1541-0420.2010.01420.x

18. 18.

    Lau B, Cole SR, Moore RD, Gange SJ. Evaluating competing adverse and beneficial outcomes using a mixture model. Statistics in Medicine. 2008;27(21):4313-4327.

    Not in our library10.1002/sim.3293

19. 19.

    Nyangweso P, Hudgens M, Fine JP.

    Not in our library

20. 20.

    Lubsen J, Kirwan BA. Combined endpoints: can we use them? Statistics in Medicine. 2002;21(19):2959-2970.

    Not in our library10.1002/sim.1300

21. 21.

    Rutten T. Hippocrates commentaries in modern age. Medicina Nei Secoli. 2005;17(2):443-468.

    Not in our library

22. 22.

    Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 2008.

    Not in our library

23. 23.

    Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. 2008.

    Not in our library

24. 24.

    Wolbers M, Koller MT, Witteman JC, Steyerberg EW. Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology. 2009;20(4):555-561.

    Not in our library10.1097/ede.0b013e3181a39056

25. 25.

    Ambrogi F, Biganzoli E, Boracchi P. Estimates of clinically useful measures in competing risks survival analysis. Statistics in Medicine. 2008;27(30):6407-6425.

    Not in our library10.1002/sim.3455

26. 26.

    Gail MH, Pfeiffer RM. On criteria for evaluating models of absolute risk. Biostatistics. 2005;6(2):227-239.

    Not in our library10.1093/biostatistics/kxi005

27. 27.

    Lubsen J, Hoes A, Grobbee D. Implications of trial results: the potentially misleading notions of number needed to treat and average duration of life gained. Lancet. 2000;356(9243):1757-1759.

    Not in our library10.1016/s0140-6736(00)03215-3

28. 28.

    Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. British Medical Journal. 1995;310(6977):452-454.

    Not in our library10.1136/bmj.310.6977.452

29. 29.

    Koller MT, Stijnen T, Steyerberg EW, Lubsen J. Meta-analyses of chronic disease trials with competing causes of death may yield biased odds ratios. Journal of Clinical Epidemiology. 2008;61(4):365-372.

    Not in our library10.1016/j.jclinepi.2007.05.009

30. 30.

    Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK. Molecular markers and death from prostate cancer. Annals of Internal Medicine. 2009;150(9):595-603.

    Not in our library10.7326/0003-4819-150-9-200905050-00005

31. 31.

    Gratwohl A, Dohler B, Stern M, Opelz G. H-Y as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study. Lancet. 2008;372(9632):49-53.

    Not in our library10.1016/s0140-6736(08)60992-7

32. 32.

    Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine. 2008;359(21):2195-2207.

    Not in our library10.1056/nejmoa0807646

33. 33.

    Koller MT, Bucher HC, Steyerberg EW. Rosuvastatin in patients with elevated C-reactive protein. The New England Journal of Medicine. 2009;360(10):1041-1042.

    Not in our library

34. 34.

    Smit C, Lindenburg K, Geskus RB, Brinkman K, Coutinho RA, Prins M. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour. Addiction. 2006;101(3):433-440.

    Not in our library10.1111/j.1360-0443.2006.01339.x

35. 35.

    Grambauer N, Schumacher M, Beyersmann J. Proportional subdistribution hazards modeling offers a summary analysis, even if misspecified. Statistics in Medicine. 2010;29(7–8):875-884.

    Not in our library10.1002/sim.3786

Cited by papers we hold 3

• Data mining in clinical big data: the frequently used databases, steps, and methodological models · 2021
  No notice
• Impact of morbidity on care need increase and mortality in nursing homes: a retrospective longitudinal study using administrative claims data · 2020
  Not checked
• Concordance for prognostic models with competing risks · 2014
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.